Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide,BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature |
| |
| Affiliation: | 1. Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China;2. Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China;3. National Engineering Research Center for Nanotechnology, Shanghai 200241, China;4. GMP Laboratory of Translational Medical Center for Stem Cell Therapy & Institute for Regenerative Medicine, National Stem Cell Translational Resource Center, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China;5. Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai 200120, China;1. Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India;2. Graduate Institute of Medicine, Yuan Ze University, Taoyuan, Taiwan;3. Department of Biotechnology, Faculty of Engineering, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India;4. Orthopaedic Research Group, Coimbatore, Tamil Nadu, India;5. Department of Orthopaedics, Government Medical College, Kaur, Tamil Nadu, India;6. Artificial Intelligence and Sensing Technologies (AIST) Research Center, University of Tabuk, Tabuk 71491, Saudi Arabia;7. Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman 19328, Jordan;8. Computer Science Department, Al al-Bayt University, Mafraq 25113, Jordan;9. MEU Research Unit, Middle East University, Amman 11831, Jordan;10. Department of Electrical and Computer Engineering, Lebanese American University, Byblos 13-5053, Lebanon;11. Applied Science Research Center, Applied Science Private University, Amman 11931, Jordan;12. School of Engineering and Technology, Sunway University Malaysia, Petaling Jaya 27500, Malaysia;1. Coenzyme R Research Institute, Tehran, Iran;2. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran;3. Department of Science, Faculty of Cellular and Molecular Biology, Ghods City Branch, Islamic Azad University, Tehran, Iran;4. Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran;5. Pharmacy Faculty, Tehran University of Medical Sciences, Tehran, Iran;6. School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran;7. Department of Genetics, Faculty of Biology, Sana Institute of Higher Education, Sari, Iran;8. PhytoPharmacology Interest Group (PPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran;9. USERN Office, Kermanshah University of Medical Sciences, Kermanshah, Iran;10. Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran;11. Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India;12. Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India;13. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran;14. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran |
| |
| Abstract: | ![]()
Four patients with limited disease small cell carcinoma of the lung were treated with high-dose cyclophosphamide (120 mg/kg over days 1 and 2), BCNU (400 mg/m2 over days 1 and 2) and VP-16 (200 mg days 1–5) used as intensification treatment after conventional chemotherapy. To ameliorate hematopoietic toxicity, autologous bone marrow cells collected and cryopreserved prior to treatment were reinfused on day 8. In three patients clinical response was evaluable. Two achieved a complete remission: one died without evidence of tumor after 3 months; the other had a regional relapse after 6 months. One patient who had progression of disease on conventional chemotherapy was refractory to high-dose treatment. Three patients developed diffuse interstitial pneumonitis 3 weeks after treatment and two died of respiratory failure. High-dose intensification chemotherapy with autologous marrow reinfusion may complement the effects of standard combination chemotherapy in small cell carcinoma of the lung. The current status of this approach is reviewed. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
